

# KDM6A expression loss is a common feature in low-grade non-invasive urothelial carcinomas of the urinary bladder.

## KEY MESSAGES

Florian Viehweger, Natalia Gorbokon, Seyma Büyücek, Henning Plage, et al. **Poster 015 (PS-27) at ECP 2024**

The KDM6A protein is completely lost in cells of 36% of pTaG2 low grade and in about >18% of pT2-4 urothelial cancers.

In patients with KDM6A deficient cancers, KDM6A IHC helps to identify flat urothelial dysplasia.

KDM6A IHC may also be useful in urin cytology and enable recognition of KDM6A deficient neoplastic cells.

Presented poster at the ECP Annual Meeting in Florence September 7-11th 2024 by Florian Viehweger.



KDM6A clone HMV311






MS



Validated Antibodies

*The antibody used in this study was KDM6A clone HMV311 of MS Validated Antibodies*




**KDM6A wild type tumor**



**Patient with KDM6A deficient low-grade cancer and dysplasia**



Urothelial dysplasia



KDM6A deficient cells